María del Carmen
Chillón Santos
Investigadora des de 2011
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicacions en col·laboració amb investigadors/es de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (13)
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas
Blood Cancer Journal, Vol. 9, Núm. 7
2015
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300
-
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
Leukemia
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
2012
-
Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1879-1888
-
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival
Annals of Hematology, Vol. 91, Núm. 12, pp. 1887-1895
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling
Leukemia, Vol. 24, Núm. 3, pp. 629-637
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
2008
-
Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma
British Journal of Haematology, Vol. 141, Núm. 2, pp. 212-215
-
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Haematologica, Vol. 93, Núm. 12, pp. 1797-1805